Compare CLDT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLDT | AVIR |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.9M | 318.0M |
| IPO Year | N/A | 2020 |
| Metric | CLDT | AVIR |
|---|---|---|
| Price | $7.81 | $6.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $9.50 | $6.00 |
| AVG Volume (30 Days) | 281.8K | ★ 518.1K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | $1.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $610.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.83 | $2.46 |
| 52 Week High | $8.45 | $5.86 |
| Indicator | CLDT | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 55.54 | 85.31 |
| Support Level | $6.81 | $3.33 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.29 | 0.28 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 49.80 | 92.99 |
Chatham Lodging Trust is a U.S.-based real estate investment trust that invests in upscale extended-stay hotels. The firm operates across various states in the U.S., including California, New York, Texas, Florida, Minnesota, Massachusetts, and Pennsylvania among others. Substantially all of the company's assets are held and operated by its Operating Partnership, Chatham Lodging, LP. Chatham Lodging LP and its subsidiaries lease the overall company's hotels. The firm operates through a single segment because of the similar economic characteristics of its hotels. Chatham's revenue streams include Room, Food and beverage, and Other. Room comprises the majority of total revenue. Chatham's hotels operate under brands which include, Hilton, Marriott, and Hyatt.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).